# Donor leukocyte telomere length emerges as a prognostic factor for transplantation outcomes

**Authors:** Hengwei Wu, Jing Yu, Yang Cao, Ruowen Wei, Wei Shi, Yunxian Yu, Zhuoyue Shi, Jimin Shi, Yi Luo, Jian Yu, Xiaoyu Lai, Lizhen Liu, Yamin Tan, Huarui Fu, Pengxu Qian, Wenming Shi, Zhongzheng Zheng, Xiaoxia Hu, He Huang, Yanmin Zhao

PMC · DOI: 10.1016/j.xinn.2025.101147 · The Innovation · 2025-10-24

## TL;DR

This study shows that donor telomere length can predict better outcomes in stem cell transplants, even when younger donors are not available.

## Contribution

The study introduces donor leukocyte telomere length as a new prognostic factor for improving donor selection in allogeneic stem cell transplantation.

## Key findings

- Long donor telomere length is linked to lower relapse rates and better survival in transplant recipients.
- Older donors with long telomeres provide outcomes comparable to younger donors.
- Older donors with short telomeres are associated with worse transplant outcomes.

## Abstract

Younger donors are preferred in allogeneic hematopoietic stem cell transplantation (allo-HSCT), but this preference may limit access for patients whose only available donors are older. This study evaluated whether donor leukocyte telomere length (LTL), in conjunction with donor age, refines donor selection strategies to improve outcomes in recipients with acute leukemia. The discovery analysis included 1,049 acute leukemia patients who underwent allo-HSCT at the First Affiliated Hospital of Zhejiang University School of Medicine, while the replication cohort included 153 recipients from three additional centers. Donor LTL was measured using real-time quantitative PCR and categorized into quartiles: short (Q1) and long (Q2-Q4). Donor age was prespecified as <40 (younger) vs. ≥40 (older) years based on clinical practice. Long donor LTL was associated with a lower cumulative incidence of relapse (CIR), improved overall survival (OS), and better relapse-free survival (RFS) in allo-HSCT recipients. Recipients of grafts from donors aged ≥40 years with short LTL had higher CIR (adjusted hazard ratio [aHR] = 1.51; 95% confidence interval [CI], 1.04–2.19), worse OS (aHR = 1.76; 95% CI, 1.20–2.58), and worse RFS (aHR = 1.53; 95% CI, 1.06–2.20) compared with recipients of grafts from donors <40 years. Immune cell profiling showed that older donors with short LTL had more CD8+CD57+HLA-DR− cells. In the replication cohort, recipients of grafts from older donors with long LTL had outcomes comparable with those of recipients with younger donors, while those with older donors and short LTL had inferior outcomes. These findings support considering donor LTL as a supplemental factor during donor evaluation, especially when younger donors are not available.

•Donor leukocyte telomere length relates to recipient outcomes after allogeneic stem cell transplantation.•Longer donor telomere length associates with lower relapse risk and better overall survival.•Telomere length may guide donor selection when younger donors (<40 years) are unavailable.

Donor leukocyte telomere length relates to recipient outcomes after allogeneic stem cell transplantation.

Longer donor telomere length associates with lower relapse risk and better overall survival.

Telomere length may guide donor selection when younger donors (<40 years) are unavailable.

## Linked entities

- **Diseases:** acute leukemia (MONDO:0010643)

## Full-text entities

- **Genes:** CD14 (CD14 molecule) [NCBI Gene 929], CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, CEACAM8 (CEA cell adhesion molecule 8) [NCBI Gene 1088] {aka CD66b, CD67, CGM6, NCA-95}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, CXCR3 (C-X-C motif chemokine receptor 3) [NCBI Gene 2833] {aka CD182, CD183, CKR-L2, CMKAR3, GPR9, IP10-R}, SPATA2 (spermatogenesis associated 2) [NCBI Gene 9825] {aka PD1, PPP1R145, tamo}, B3GAT1 (beta-1,3-glucuronyltransferase 1) [NCBI Gene 27087] {aka CD57, GLCATP, GLCUATP, HNK1, LEU7, NK-1}, CCR7 (C-C motif chemokine receptor 7) [NCBI Gene 1236] {aka BLR2, CC-CKR-7, CCR-7, CD197, CDw197, CMKBR7}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, CCR4 (C-C motif chemokine receptor 4) [NCBI Gene 1233] {aka CC-CKR-4, CD194, CKR4, CMKBR4, ChemR13, HGCN:14099}, CD24 (CD24 molecule) [NCBI Gene 100133941] {aka CD24A}, IL2RA (interleukin 2 receptor subunit alpha) [NCBI Gene 3559] {aka CD25, IDDM10, IL2R, IMD41, TCGFR, p55}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, FUT4 (fucosyltransferase 4) [NCBI Gene 2526] {aka CD15, ELFT, FCT3A, FUC-TIV, FUTIV, LeX}, IL3RA (interleukin 3 receptor subunit alpha) [NCBI Gene 3563] {aka CD123, IL-3R-alpha, IL3R, IL3RAY, IL3RX, IL3RY}, CD34 (CD34 molecule) [NCBI Gene 947], CCR6 (C-C motif chemokine receptor 6) [NCBI Gene 1235] {aka BN-1, C-C CKR-6, CC-CKR-6, CCR-6, CD196, CKR-L3}, CXCR5 (C-X-C motif chemokine receptor 5) [NCBI Gene 643] {aka BLR1, CD185, MDR15}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CD27 (CD27 molecule) [NCBI Gene 939] {aka S152, S152. LPFS2, T14, TNFRSF7, Tp55}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, ITGAX (integrin subunit alpha X) [NCBI Gene 3687] {aka CD11C, SLEB6}
- **Diseases:** immune dysfunction (MESH:D007154), acute lymphoblastic leukemia (MESH:D054198), T (MESH:D001260), malignant diseases (MESH:D009369), infection (MESH:D007239), age-related disease (MESH:D010024), Acute GVHD (MESH:D006086), LTL (MESH:D007960), CIR (MESH:D012090), leukemia (MESH:D007938), hematologic diseases (MESH:D006402), NRM (MESH:D003643), myelodysplastic syndrome (MESH:D009190), acute leukemia (MESH:D015470), severe (MESH:D045169), aplastic anemia (MESH:D000741)
- **Chemicals:** nitrogen (MESH:D009584), cisplatin (MESH:D002945), CyTOF (-), heavy metal (MESH:D019216), Steroid (MESH:D013256), water (MESH:D014867), Ir (MESH:D007495)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957556/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12957556/full.md

## References

27 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957556/full.md

---
Source: https://tomesphere.com/paper/PMC12957556